

IRELL & MANELLA LLP
 1800 Avenue of the Stars, Suite 900
 Los Angeles, CA 90067-4276
 Facsimile No.: (310) 203-7199
 Telephone No.: (310) 277-1010
 Facsimile Dept. Ext.: 8200

RECEIVED

JUN 10 2002

TECH CENTER 1600/2900

This communication may contain confidential or privileged information and may constitute inside information. It is intended only for the addressee. Any distribution, reading, copying, or use of this communication by anyone other than the addressee is strictly prohibited and may be unlawful. If you received this in error, please notify us immediately by telephone, and return the original communication to us at the above address by mail. You will be reimbursed for your reasonable expenses. Thank you.

RECEIVED

JUN 10 2002

VIA FACSIMILE
TECH CENTER 1600/2900Sent by: CynthiaReference No.: 15-75

Date: May 15, 2002

Facsimile No.: (703)-308-7751

Office Telephone No.: (703) 308-1202

To: Commissioner of Patents and
Trademarks

From: Carol A. Schneider, Ph.D., J.D.

Received by: _____

cc:

Time: _____

No. of Pages:
(including cover page)

8

Serial No.: 09/976,598

Filed: October 12, 2001

For: DISEASE PREVENTION BY REACTIVATION OF THE THYMUS

Group Art Unit: 1646

Our Ref: 156857-0044

Please see attached Request for Corrected Filing Receipt and Preliminary Amendment

Original will be sent via: Mail Pouch Messenger Overnight Courier Will not be sent

Patent
Atty Docket No. 156857-0044IN THE UNITED STATES PATENT AND TRADEMARK OFFICE **RECEIVED**

In re the Application of:) JUN 10 2002
Richard L. BOYD) Group Art Unit: 1646
Serial No.: 09/976,598) Examiner: Not yet assigned TECH CENTER 1600/2900
Filed: October 12, 2001)
For: DISEASE PREVENTION BY)
REACTIVATION OF THE THYMUS)

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicant respectfully requests that a corrected Filing Receipt issue for the above-referenced application. The Filing Receipt issued by the U.S. Patent and Trademark Office does not indicate all of the previously filed applications from which priority is claimed.


The original specification (page 1 enclosed) did not contain all of the prior art information. In that regard, submitted herewith is a Preliminary Amendment which corrects the first paragraph of the specification. A copy of the Filing Receipt with changes noted thereon is also attached.

On the Filing Receipt, below the list of the Applicant(s), please insert as follows:

CERTIFICATE OF TRANSMISSION

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being transmitted via facsimile ((703) 308-7751) on the date shown below to the Commissioner for Patents, Washington, D.C. 20231.

May 15, 2002
Date of Transmission


Janet Kornbluth

Patent
Atty Docket No. 156857-0044
Serial No.: 09/976,598

DOMESTIC PRIORITY DATA AS CLAIMED BY APPLICANT:

This application is a CIP of 09/965,395	09/26/2001
which is a CIP of 09/755,965	01/05/2001
and a CIP of 09/755,646	01/05/2001
and a CIP of 09/755,983	01/05/2001
and a CIP of 09/758,910	01/10/2001
and said 09/755,965 and 09/755,646 and 09/755,983	
and 09/758,910	
are all CIPS of 09/795,286	10/13/2000
and CIPS of 09/795,302	10/13/2000
and said 09/795,286 AND 09/795,302	
are both CIPS of PCT/AU00/00329	04/17/2000

FOREIGN APPLICATIONS:

AUSTRALIA PR0745	10/13/2000
PCT/AU00/00329	04/17/2000
AUSTRALIA PP9778	04/15/1999

Applicants believe that no fee is necessary at this time. However, if any fees are associated with this request, the Commissioner is authorized to charge the necessary amount from our Deposit Account No. 09-0946.

Respectfully Submitted,

Dated: May 15, 2002



Carol A. Schneider, Ph.D., J.D.
Registration No. 34,923

IRELL & MANELLA LLP
1800 Avenue of the Stars, Suite 900
Los Angeles, CA 90067
Telephone: (310) 277-1010
Facsimile: (310) 203-7199

156857/0044

Patent

DISEASE PREVENTION BY REACTIVATION OF THE THYMUS

[0001] This application is a continuation-in-part of U.S. Serial No. ~~not yet available~~ filed September 26, 2001, which is a continuation in part of each of U.S. Serial No.

09/755,965 filed January 5, 2001, U.S. Serial No. 09/755,646 filed January 5, 2001, U.S.

5 Serial No. 09/755,983 filed January 5, 2001, and U.S. Serial No. 09/758,910 filed January 10, 2001, each of which is a continuation-in-part of U.S. Serial No. 09/795,286 filed October 13, 2000 which is a continuation-in-part of AU provisional application PR0745 filed October 13, 2000, and of U.S. Serial No. 09/795,302 filed October 13, 2000 which is a continuation-in-part of PCT AU00/00329 filed April 17, 2000, which is a PCT filing of AU provisional application

10 PP9778 filed April 15, 1999, each of which is incorporated herein by reference.

FIELD OF THE INVENTION

[0002] The present disclosure is in the field of disease prevention. In particular this invention is in the field of stimulating a patient's immune system through reactivation of the thymus, and optionally using gene therapy of hematopoietic stem cells (HSC), hematopoietic

15 progenitor cells, epithelial stem cells or bone marrow.

BACKGROUND OF THE INVENTION

THE IMMUNE SYSTEM

[0003] The major function of the immune system is to distinguish "foreign" antigens from "self" and respond accordingly to protect the body against infection. In normal immune

20 responses, the sequence of events involves dedicated antigen presenting cells (APC) capturing foreign antigen and processing it into small peptide fragments which are then presented in clefts of major histocompatibility complex (MHC) molecules on the APC surface. The MHC molecules can either be of class I expressed on all nucleated cells (recognized by cytotoxic T cells (Tc)) or of class II expressed primarily by cells of the immune system (recognized by helper

25 T cells (Th)). Th cells recognize the MHC II/peptide complexes on APC and respond; factors released by these cells then promote the activation of either of both Tc cells or the antibody producing B cells which are specific for the particular antigen. The importance of Th cells in virtually all immune responses is best illustrated in HIV/AIDS where their absence through destruction by the virus causes severe immune deficiency eventually leading to death.

30 Inappropriate development of Th (and to a lesser extent Tc) can lead to a variety of other diseases such as allergies, cancer and autoimmunity.

Preliminary Class
530

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).